Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 14/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16693604 | 0.84 | RAB9A (0.50) | SMN1; SMN2LMNATSHRNPC1RAB9A | |
| SCHEMBL16691854 | 0.83 | NAMPT (0.60) | NAMPTSMN1; SMN2ALDH1A1LMNAHIF1A | |
| SCHEMBL26725267 | 0.76 | BACE1 (0.50) | SMN1; SMN2LMNATP53NPC1RAB9A | |
| SCHEMBL20582644 | 0.76 | LMNA (0.53) | NAMPTSMN1; SMN2ALDH1A1LMNAHIF1A | |
| SCHEMBL16693550 | 0.76 | NAMPT (0.64) | NAMPTSMN1; SMN2ALDH1A1LMNAHIF1A | |
| SCHEMBL9906904 | 0.73 | RAB9A (0.65) | NAMPTSMN1; SMN2ALDH1A1LMNAHIF1A | |
| SCHEMBL31022619 | 0.73 | NAMPT (0.66) | NAMPTSMN1; SMN2ALDH1A1LMNAHIF1A | |
| SCHEMBL19313222 | 0.73 | TGM2 (0.44) | SMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL1399969 | 0.72 | SMN1; SMN2 (0.53) | NAMPTSMN1; SMN2ALDH1A1LMNAHIF1A | |
| SCHEMBL790699 | 0.71 | NAMPT (0.73) | NAMPTSMN1; SMN2LMNAHIF1ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9321774-B2 | Pyrrolobenzodiazepines | MEDIMMUNE LIMITED (GB) | 2016-04-26 | — | — | US | disclosed |
| US-20150126495-A1 | PYRROLOBENZODIAZEPINES | MEDIMMUNE LIMITED (GB) | 2015-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150126495-A1 | PYRROLOBENZODIAZEPINES | CHRM1, CHRM2, CHRM3 | NAMPT 4373/4885SMN1; SMN2 1246/4885ALDH1A1 3148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.